AtriCure, Inc. (NASDAQ:ATRC) Shares Sold by Wasatch Advisors LP

Wasatch Advisors LP lowered its stake in shares of AtriCure, Inc. (NASDAQ:ATRC) by 2.6% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 769,252 shares of the medical device company’s stock after selling 20,562 shares during the period. Wasatch Advisors LP owned 1.58% of AtriCure worth $21,570,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Canada Pension Plan Investment Board boosted its stake in shares of AtriCure by 187.7% during the second quarter. Canada Pension Plan Investment Board now owns 110,669 shares of the medical device company’s stock valued at $2,520,000 after acquiring an additional 72,200 shares during the last quarter. Renaissance Technologies LLC increased its stake in shares of AtriCure by 12.8% during the 2nd quarter. Renaissance Technologies LLC now owns 171,700 shares of the medical device company’s stock valued at $3,910,000 after acquiring an additional 19,500 shares during the last quarter. SG Americas Securities LLC purchased a new position in shares of AtriCure during the 3rd quarter worth about $488,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its position in shares of AtriCure by 31.5% in the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 500,649 shares of the medical device company’s stock worth $14,038,000 after acquiring an additional 119,929 shares during the last quarter. Finally, Assenagon Asset Management S.A. boosted its position in shares of AtriCure by 151.6% in the third quarter. Assenagon Asset Management S.A. now owns 229,130 shares of the medical device company’s stock worth $6,425,000 after acquiring an additional 138,046 shares during the last quarter. Institutional investors and hedge funds own 99.11% of the company’s stock.

Analysts Set New Price Targets

ATRC has been the subject of several research analyst reports. Canaccord Genuity Group upped their price target on shares of AtriCure from $49.00 to $53.00 and gave the stock a “buy” rating in a research report on Wednesday, October 30th. Oppenheimer upped their price objective on AtriCure from $32.00 to $36.00 and gave the stock an “outperform” rating in a report on Wednesday, October 30th. StockNews.com upgraded AtriCure from a “sell” rating to a “hold” rating in a report on Saturday, September 14th. Needham & Company LLC boosted their price target on AtriCure from $34.00 to $40.00 and gave the company a “buy” rating in a research report on Wednesday, October 30th. Finally, UBS Group raised their price objective on AtriCure from $35.00 to $40.00 and gave the stock a “buy” rating in a report on Wednesday, October 30th. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $41.00.

AtriCure Price Performance

Shares of NASDAQ ATRC opened at $36.16 on Friday. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.62 and a quick ratio of 2.59. AtriCure, Inc. has a 1-year low of $18.94 and a 1-year high of $39.04. The company has a market capitalization of $1.76 billion, a price-to-earnings ratio of -43.57 and a beta of 1.41. The business has a 50-day moving average of $31.71 and a 200-day moving average of $26.39.

AtriCure (NASDAQ:ATRC) last released its quarterly earnings results on Tuesday, October 29th. The medical device company reported ($0.17) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.02. AtriCure had a negative return on equity of 8.12% and a negative net margin of 8.70%. The firm had revenue of $115.91 million during the quarter, compared to analysts’ expectations of $112.23 million. During the same quarter in the prior year, the business earned ($0.20) EPS. AtriCure’s quarterly revenue was up 17.9% compared to the same quarter last year. On average, equities analysts anticipate that AtriCure, Inc. will post -0.72 EPS for the current fiscal year.

About AtriCure

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.